Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown Pde N, Pedersen LM. Mylam KJ, et al. Among authors: kostakoglu l. Leuk Lymphoma. 2015 Jul;56(7):2005-12. doi: 10.3109/10428194.2014.975800. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25330442
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M. Hutchings M, et al. Among authors: kostakoglu l. J Clin Oncol. 2014 Sep 1;32(25):2705-11. doi: 10.1200/JCO.2013.53.2838. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071108
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.
Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M. Gallamini A, et al. Among authors: kostakoglu l. Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218. Epub 2014 Mar 21. Haematologica. 2014. PMID: 24658820 Free PMC article.
Comparison of 11 automated PET segmentation methods in lymphoma.
Weisman AJ, Kieler MW, Perlman S, Hutchings M, Jeraj R, Kostakoglu L, Bradshaw TJ. Weisman AJ, et al. Among authors: kostakoglu l. Phys Med Biol. 2020 Nov 27;65(23):235019. doi: 10.1088/1361-6560/abb6bd. Phys Med Biol. 2020. PMID: 32906088
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
Eertink JJ, Burggraaff CN, Heymans MW, Dührsen U, Hüttmann A, Schmitz C, Müller S, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Carr R, Czibor S, Györke T, Ceriani L, Zucca E, Hutchings M, Kostakoglu L, Loft A, Fanti S, Wiegers SE, Pieplenbosch S, Boellaard R, Hoekstra OS, Zijlstra JM, de Vet HCW. Eertink JJ, et al. Among authors: kostakoglu l. Blood Adv. 2021 May 11;5(9):2375-2384. doi: 10.1182/bloodadvances.2021004467. Blood Adv. 2021. PMID: 33944897 Free PMC article.
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
Mones JV, Coleman M, Kostakoglu L, Furman RR, Chadburn A, Shore TB, Muss D, Stewart P, Kroll S, Vallabhajosula S, Goldsmith SJ, Leonard JP. Mones JV, et al. Among authors: kostakoglu l. Leuk Lymphoma. 2007 Feb;48(2):342-8. doi: 10.1080/10428190601059720. Leuk Lymphoma. 2007. PMID: 17325895 Clinical Trial.
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD; Cancer Leukemia Group B. Kostakoglu L, et al. Leuk Lymphoma. 2012 Nov;53(11):2143-50. doi: 10.3109/10428194.2012.676173. Epub 2012 Aug 28. Leuk Lymphoma. 2012. PMID: 22421007 Free PMC article. Clinical Trial.
168 results